Roquefort Therapeutics PLC Notice of AGM - Correction (5577O)
June 13 2022 - 2:00AM
UK Regulatory
TIDMROQ
RNS Number : 5577O
Roquefort Therapeutics PLC
13 June 2022
13 June 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Notice of Annual General Meeting - Correction
Following the announcement made on 7 June 2022 giving notice of
the Annual General Meeting (the "AGM") of the Company to be held on
30 June 2022, and the publication and despatch of a circular to
shareholders containing notice of the resolutions to be considered
at the AGM (the "Notice") and form of proxy, it has come to the
attention of the Company that the Notice contains a typographical
error.
The explanatory notes at paragraph 2 contained on page 7 of the
Notice incorrectly states that "Pursuant to regulation 41 of the
Uncertificated Securities Regulations 2001 (as amended) and
paragraph 18(c) of the Companies Act 2006 (Consequential
Amendments) (Uncertificated Securities) Order 2009, the Company
specifies that only those members registered on the Company's
register of members at close of business on 27 June 2022 shall be
entitled to attend, speak and vote at the Annual General Meeting
(or if the meeting is adjourned, those members registered on the
register of members of the Company not later than 48 hours before
the time fixed for the adjourned meeting).". The Notice should
instead state that "...the Company specifies that only those
members registered on the Company's register of members at 10am on
28 June 2022 shall be entitled to attend, speak and vote at the
Annual General Meeting (or if the meeting is adjourned, those
members registered on the register of members of the Company not
later than 48 hours before the time fixed for the adjourned
meeting).".
As this was a clerical error, no new Notice will be posted to
shareholders; however, a copy of the corrected Notice is available
on the following page of the Company's website:
https://www.roquefortplc.com/category/shareholder-documents/
-Ends-
Enquiries:
Roquefort Therapeutics plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George
Beale
+44 (0)20 7466
Optiva Securities Limited (Broker) 5000
+44 (0)20 3411
Christian Dennis 1881
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech
company developing products through the pre-clinical phase prior to
partnering or selling to big pharma. The Company is a pre-clinical
biotech company focused on developing first in class Midkine
targeting drugs for the treatment of cancer.
Through extensive research resulting in validation through
publication in over 1,000 scientific journals, Roquefort
Therapeutics has identified the potential to exploit the broad
therapeutic potential of Midkine for a number of clinical
indications of unmet needs. Roquefort Therapeutics holds an
exclusive licence to the largest global IP portfolio on Midkine.
The Midkine blocking drug development markets have significant
global market potential (in the multi-billion dollars). Roquefort
Therapeutic's pre-clinical program is currently underway with an
initial focus on cancer.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAGRGDLDUBDGDD
(END) Dow Jones Newswires
June 13, 2022 02:00 ET (06:00 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jul 2023 to Jul 2024